 |
|
|
June 29, 2007
| Torii Pharmaceutical Co., Ltd. |
| Toray Industries, Inc. |
|
|
Torii, Toray starts to Co-Promote Hemoperfusion
absorption column
"Toraymyxin" for removing endotoxin |
|
Torii Pharmaceutical Co., Ltd. (headquarters:
Tokyo; president: Norihiko Matsuo; hereinafter referred to as
"Torii") and Toray Industries, Inc. (headquarters:
Tokyo; president: Sadayuki Sakakibara; hereinafter referred
to as "Toray") announced that the companies would
start joint promotion of "Toraymyxin" (PMX-20R, PMX-05R)
from July 2, 2007 in Japan, a hemoperfusion absorption column
for removing endotoxin, which was developed by Toray. Currently,
Toray manufactures "Toraymyxin" which has been marketed
by Toray Medical Co., Ltd. (headquarters: Tokyo; president:
Motonaga Tanaka), a wholly owned subsidiary of Toray.
"Toraymyxin", a blood purification device (column),
absorbs the bacterial toxin (endotoxin) that causes sepsis and
septic shock using a special fiber. It consists of a plastic
cylindrical container filled with a special fiber composite
immobilized with the antibiotic polymyxin B, which has high
affinity for endotoxin. Toray in 1993 received approval for
manufacturing and marketing of the product from then the "Health
and Welfare Ministry of Japan," and Toray Medical has been
marketing it since 1994. "Toraymyxin" is designed
to selectively absorb and remove endotoxin in the bloodstream,
which is believed to be responsible for sepsis.
Torii, Toray and Toray Medical believe that the tie-up would
enable provision of superior products and information faster
and in a more detailed manner to medical experts who engage
in urgent medical treatment and intensive care, leading to further
contribution to improvements of patients as well as advancement
of medical technology.
|
|
|
| |
|
|
|
|
